Baricitinib (Olumiant; Eli Lilly), an oral Janus kinase (JAK) 1/2 inhibitor, led to significant scalp, eyelash, and eyebrow hair regrowth at 52 weeks in adolescents with severe alopecia areata, ...

Long term data were announced from a phase 3 trial evaluating baricitinib in adolescents aged 12 to less than 18 years with severe alopecia areata.

Explore the latest advances in alopecia areata treatment, including FDA-approved JAK inhibitors and promising topical ...

New results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) showed once-daily, oral baricitinib 4 mg helped ...

More than half of adolescents treated with baricitinib achieved complete or near-complete scalp hair regrowth at 1 year, with ...

Fifty-four percent of patients ages 12 to 18 with severe alopecia noticed hair regrowth when given 4-mg of Olumiant (oral baricitinib), according to results of a study presented this week at the 2025 ...

Nektar Therapeutics is expected to announce topline data from the REZOLVE-AA trial in December 2025. The Food and Drug Administration (FDA) has granted Fast Track designation to rezpegaldesleukin for ...

"Lilly and Incyte to seek approval of alopecia JAK inhibitor in children" was originally created and published by Clinical ...

Credit: SUN Pharma. Leqselvi is supplied as a tablet containing 8mg of deuruxolitinib. Prior to initiating treatment with Leqselvi, certain evaluations and immunizations are recommended. Leqselvi ™ ...

Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.’ This study aims to assess the safety and efficacy of ritlecitinib, a potential treatment for ...

SAN FRANCISCO, July 29, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ...